medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 6

<< Back Next >>

Med Int Mex 2018; 34 (6)

Control and evaluation of microalbuminuria in a population of the state of Nayarit, Mexico. Study conducted by self-measurement on loan of blood pressure

Delgado-Mejía M, Delgado-Astorga C, Ávalos-Ruvalcaba T, Paredes-Casillas P, González-González E

Language: Spanish
References: 39
Page: 864-873
PDF size: 386.03 Kb.


ABSTRACT

Background: There are precedents that the strict control of the blood pressure figures can have a favorable impact avoiding the development of microalbuminuria, and therefore preventing the appearance of nephropathy, as well as significantly reducing fatal outcomes due to cardiovascular and cerebrovascular disease.
Objective: To show that strict control of tension figures can impact decreasing the microalbuminuria.
Material and Method: An observational and descriptive study was done from January to December 2017 with patients with an established diagnosis of type 2 diabetes mellitus and/or systemic hypertension, with random selection. These patients were incorporated into a Self-Commissioning Protocol to loan blood pressure. Patients with chronic kidney disease were not included.
Results: There were included 200 patients. The correlation between multiple variables and the presence of microalbuminuria was measured finding a statistically significant correlation when segmenting patients according to the ACC/AHA 2017 classification and after adjusting the antihypertensive dose with p = 0.00001.
Conclusions: Treatment should be adjusted based on the patient’s blood pressure, regardless of whether the treatment is with IECAS or ARA II.


REFERENCES

  1. World Health Organization. The Diabetes Program 2004. (Accessed September 21, 2004).

  2. Ramuzzi G, Shieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145- 51.

  3. Ritz E. Albuminuria and vascular damage- the vicious twins. N Engl J Med 2003;348:2349-52.

  4. Gall MA, Jouggard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997;324:783-8.

  5. Adler AL, Stevens RJ, Manley SE, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.

  6. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warran JH. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285-93.

  7. Parving HH, Lehenert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

  8. Mogensen CE. Microalbuminuria predicts clinical proteinuria early mortality in maturity-onset diabetes. N Engl J Med 1984;310,356-60.

  9. Nelson RG, Knowler WC, Pettit DJ, Bennet PH. Assessing risk of overt nephropaty in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991;151:1761-60.

  10. Schrier RW, Estacio RO, Esler A, Mehler P. Effect of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61(3):1086-1097.

  11. Eurich DT, Majumdar SR, Tsuyuki RT, Johanson JA. Reduced mortality associated with the use of ACE Inhibitors in patients with type 2 diabetes. Diabetes Care 2004;27:1330-4.

  12. Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner & Rectors. The Kidney, 7th ed. Vol. 2. Philadephia: Saunders, 2004;1777-818.

  13. Selvin E, Marinopoulus S, Berkenblit G, et al. Meta-analysis: Glycosyladehemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.

  14. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997;157:1413-8.

  15. Brenner BM, Cooper ME. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861.

  16. Ravit M, Brosh D, Levi Z, Bar Dayan Y. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuria patients with type 2 diabetes mellitus a randomized controlled trial. Ann Intern Med 1998;128:982-8.

  17. Calvo-Vargas CG, Padilla V, Medina M. Reproducibility end cost of home blood pressure using the “Loaned selfmeasurement model”. Blood Pressure Monit 2001;6:1-8.

  18. Calvo-Vargas CG, Rubio Guerra AF, Galarza-Delgado D, Garcia C, Delgado-Mejía M. Eficacia del valsartan y la hidroclorotiazida en el tratamiento de la hipertensión arterial esencial. Estudio realizado mediante la automedicion a préstamo de la presión arterial. Med Int Mex 2002;18(2):67-74.

  19. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313(6):603-615.

  20. Ruggementi P, Remuzzi G. The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. Curr- Opin Nephrol Hypertens 1997;6:141-51.

  21. UK Prospective Diabetes Study Group. (UKPDS) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. Lancet 1999;354:602.

  22. BENEDICT Group. The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT): Design and baseline characteristics. Control Clin Trials 2003;24:442-61.

  23. High blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13. BMJ 1999;318-29.

  24. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention For Endpoint reduction in hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002;359:1004-10.

  25. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

  26. Heart outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the (HOPE) study, and MICRO-HOPE substudy. Lancet 2000;355:253-59. (Erratum, Lancet 2000;356:860).

  27. Viberty G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbumiuria JAMA 1994;271:275-9.

  28. Kaplan NM. Clinical Hypertension. 7ª ed. Baltimore: Williams & Wilkins, 1998.

  29. Calvo GC. La atención del paciente con hipertensión arterial. Un enfoque para el consultorio. Mexico: JGH editores, 1999.

  30. Calvo-Vargas CG. Nuevos retos del control de la hipertensión arterial en México. Rev Med IMSS (Mex) 1998;36(3):199-205.

  31. Thijs L, Staessen JA, Celis H, de Gaudemaris R, Imail Y, Julius S, et al. Reference values for self-recorded blood pressure: meta-analysis of summary date. Arch Intern Med 1998;158:481-8.

  32. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis 2014;63(Suppl 2):S3-S21.

  33. Caramori MI, Fioretto P, Maurer M. Low glomerular filtration rate in normoalbuminuric type I diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003;52(4):1056-1640.

  34. Dwyer JP, Parving HH, Ravid M, Ramuzzi G, Lewis JB. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND Study. Cardio Renal Med 2012;2(1):1-10.

  35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development end progression of long-term complications in insulin dependent diabetes mellitus . N Engl J Med 1993;329(14):977-986.

  36. Chakkarwar VA. Smoking in diabetic nephropathy sparks in the fuel tank? Word J Diabetes 2012;3(12):186-195.

  37. Clinical Practice Guidelines. Diabetes Care 2013;36(Suppl 1):529-531.

  38. Accord Study Group. Cushman WC, Evans GW, Bryngton RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1575-1585.

  39. Parving H, et al, for the ALTITUDE Investigators. N Engl J Med 2012;367:2204-2213.




2020     |     www.medigraphic.com